Engineered immune cells take on kidney cancer in first human test
Disease control
Not yet recruiting
This early-phase trial tests a new treatment for advanced kidney cancer that has spread. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The study will enroll 18 adults and focus on safety and finding the right dose, w…
Phase: PHASE1 • Sponsor: Hrain Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC